All In Biotech

Drug Trial Radar · NCT07906665

A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 1 Placebo-Controlled Study of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS): Evaluation of Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 22, 2027

Primary completion

Mar 1, 2028

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Sachi Bioworks Inc.Industry
Sponsor type
Industry
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human study of NI112, an investigational medicine given as an injection under the skin, in adults with amyotrophic lateral sclerosis (ALS). The purpose of the study is to find out how safe NI112 is, how well it is tolerated, and how the body handles it after a single dose. Up to 40 adults with ALS will take part at up to three study centers in the United States. Participants will be assigned by chance to receive either a single dose of NI112 or a single dose of placebo (sterile salt water). The study tests up to seven dose levels, one after another, beginning with the lowest dose. A Safety Review Board reviews the safety information from each group of participants before the next, higher dose is given to a new group. Each participant stays in the hospital for 24 hours after the injection for safety monitoring and blood sampling, and returns for follow-up visits on Day 8 and Day 28. The study also measures the amount of NI112 in blood and in spinal fluid.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • NI112Drug

    Antisense Nanoligomer administered at 40 mg/mL, as a single subcutaneous injection on Day 1. Doses above 40 mg are divided across two injection sites with no more than 1.5 mL per site.

  • PlaceboDrug

    Sterile normal saline (0.9% sodium chloride), administered as a single subcutaneous injection on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With incidence and severity of treatment-emergent adverse eventsTime frame: Day 1 through Day 28
  2. Number of Participants With incidence and severity of treatment-emergent serious adverse eventsTime frame: Day 1 through Day 28
  3. Number of Participants With Treatment-Emergent Clinically Significant Blood Pressure AbnormalitiesTime frame: Day 1 through Day 28
  4. Number of Participants With Treatment-Emergent Clinically Significant Pulse Rate AbnormalitiesTime frame: Day 1 through Day 28
  5. Number of Participants With Treatment-Emergent Clinically Significant Respiratory Rate AbnormalitiesTime frame: Day 1 through Day 28
  6. Number of Participants With Treatment-Emergent Clinically Significant Body Temperature AbnormalitiesTime frame: Day 1 through Day 28
  7. Number of Participants With Treatment-Emergent Clinically Significant Neurological Examination FindingsTime frame: Day 1 through Day 8
  8. Number of Participants With Treatment-Emergent Clinically Significant Physical Examination FindingsTime frame: Day 1 through Day 8
  9. Number of Participants With Treatment-Emergent Clinically Significant 12-Lead Electrocardiogram Abnormalities, Including QT Interval Corrected by Fridericia's Formula (QTcF)Time frame: Day 1 through Day 28
  10. Number of Participants With Treatment-Emergent Clinically Significant Hematology AbnormalitiesTime frame: Day 1 through Day 28
  11. Number of Participants With Treatment-Emergent Clinically Significant Serum Chemistry AbnormalitiesTime frame: Day 1 through Day 28
  12. Number of Participants With Treatment-Emergent Clinically Significant Urinalysis AbnormalitiesTime frame: Day 1 through Day 28
  13. Number of Participants With discontinuations due to adverse eventsTime frame: Day 1 through Day 28
  14. Maximum tolerated dose of single-dose NI112Time frame: From the first dose of the first cohort through the Day 28 visit of the last subject in the highest cohort evaluated, approximately 13 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona, Scottsdale, AZ

    Scottsdale, Arizona

  • Mayo Clinic Florida, Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Rochester, Rochester, MN

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.